transitioning from semaglutide to tirzepatide Switching Semaglutide vs. Tirzepatide: Which is
Description
Novo Nordisk has announced headline results from the STEP UP study, a phase 3b trial in the global STEP programme, which revealed the trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2mg versus placebo.STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2mg compared to semaglutide 2.4mg and placebo, all administered once weekly
In the case that we present, the patient stopped duraglutide abruptly due to lack of insurance coverage and regained the weight she had lost within a month
West developed half inch and five eighths inch rigid needle shields made polyisoprene and a bromobutyl rubber to provide an added safety solution for prefilled syringes to enhance safety and convenience.
Discover which patient profiles benefit most from semaglutide and tirzepatide therapy
LLMs mapped patient language to medical terminology at a scale that wasn't possible before
